Inrebic
Drug
Celgene Corporation
Total Payments
$1.2M
Transactions
1,501
Doctors
946
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.2M | 1,501 | 946 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $715,932 | 12 | 60.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $298,935 | 73 | 25.3% |
| Travel and Lodging | $90,268 | 162 | 7.6% |
| Consulting Fee | $45,351 | 13 | 3.8% |
| Food and Beverage | $30,609 | 1,219 | 2.6% |
| Education | $191.18 | 22 | 0.0% |
Payments by Type
Research
$715,932
12 transactions
General
$465,354
1,489 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| (FEDR-CP-002 (PMC)) A Phase 1, Open-label, 2-part Study to Evaluate the Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects (BMS Study Number: CA054-P07) (FEDR-CP-002) | Celgene Corporation | $420,841 | 0 |
| A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy & Safety Study of Fedratinib in Subjects w/ DIPSS-Intermediate or High-Risk PMF, post-PV MF, or post-ET MF & Previously Treated w/ Ruxolitinib incl. Sub-study w/ concomitant Luspatercept for anemia (FEDR-MF-001) | Celgene Corporation | $192,835 | 0 |
| A Phase 1, Open-Label, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Fedratinib in Subjects with Moderate and Severe Hepatic Impairment Compared with Healthy Subjects (BMS Study Number: CA054-P06) (FEDR-CP-001) | Celgene Corporation | $102,256 | 0 |
Top Doctors Receiving Payments for Inrebic
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Rochelle Ablah | — | Oklahoma City, OK | $715,977 | 14 |
| , MD | Hematology & Oncology | Jersey City, NJ | $40,896 | 26 |
| , M.D | Hematology & Oncology | Omaha, NE | $33,285 | 24 |
| , MD | Medical Oncology | Baltimore, MD | $33,147 | 20 |
| , MD | Hematology & Oncology | Pembroke Pines, FL | $30,737 | 28 |
| , MD | Hematology & Oncology | Orlando, FL | $27,263 | 20 |
| , MD | Hematology & Oncology | Minneapolis, MN | $21,564 | 16 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $18,466 | 14 |
| , M.D | Hematology | Hawthorne, NY | $18,395 | 10 |
| , MD | Internal Medicine | New York, NY | $18,292 | 12 |
| Bart Scott | Medical Oncology | Seattle, WA | $16,266 | 9 |
| , M.D | Specialist | Owing Mills, MD | $15,736 | 13 |
| , MD | Hematology & Oncology | San Diego, CA | $13,221 | 13 |
| , M.D | Internal Medicine | Duarte, CA | $10,421 | 15 |
| , MD | Internal Medicine | Orlando, FL | $10,339 | 8 |
| , MD | Hematology & Oncology | Boston, MA | $9,264 | 5 |
| , MD | Hematology & Oncology | Scarborough, ME | $8,482 | 8 |
| , M.D | Hematology & Oncology | Indianapolis, IN | $7,775 | 6 |
| , M.D | Internal Medicine | Oklahoma City, OK | $7,360 | 7 |
| , MD | Medical Oncology | Dallas, TX | $7,268 | 6 |
| , MD | Hematology & Oncology | New Orleans, LA | $6,990 | 6 |
| , MD | Hematology & Oncology | Binghamton, NY | $6,441 | 5 |
| , MD | Hematology & Oncology | Memphis, TN | $6,116 | 8 |
| , M.D | Hematology & Oncology | Miami, FL | $6,015 | 8 |
| , M.D | Specialist | Sacramento, CA | $5,989 | 3 |
Ad
Manufacturing Companies
- Celgene Corporation $1.2M
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 946
- Transactions 1,501
About Inrebic
Inrebic is a drug associated with $1.2M in payments to 946 healthcare providers, recorded across 1,501 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2019. In 2019, $1.2M was paid across 1,501 transactions to 946 doctors.
The most common payment nature for Inrebic is "Unspecified" ($715,932, 60.6% of total).
Inrebic is associated with 3 research studies, including "(FEDR-CP-002 (PMC)) A Phase 1, Open-label, 2-part Study to Evaluate the Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects (BMS Study Number: CA054-P07) (FEDR-CP-002)" ($420,841).